FAP-IL2v实现黑色素瘤患者持续缓解长达43.4个月! Simlukafusp alfa (FAP-IL2v)是一种单体免疫细胞因子,2024年7月1日,《CLINICAL CANCER RESEARCH》发表了FAP-IL2v在晚期/转移性实体瘤患者中的I期临床(NCT02627274)疗效,在该试验中,FAP-IL2v显示出初步抗肿瘤活性。 截图来源于参考资料2,侵权请联系删除 该试验...
We evaluated the antitumour activity and safety of FAP-IL2v plus atezolizumab in recurrent and/or metastatic cervical squamous cell carcinoma (SCC) in a phase 2 basket study ( NCT03386721 ). Methods Patients with confirmed metastatic, persistent or recurrent cervical SCC who had progressed on ≥...
FAP-IL2v实现黑色素瘤患者持续缓解长达43.4个月! Simlukafusp alfa (FAP-IL2v)是一种单体免疫细胞因子,2024年7月1日,《CLINICAL CANCER RESEARCH》发表了FAP-IL2v在晚期/转移性实体瘤患者中的I期临床(NCT02627274)疗效,在该试验中,FAP-IL2v显示出初步抗肿瘤活性。 截图来源于参考资料2,侵权请联系删除 该试验...
Patients received FAP-IL2v 10 mg plus atezolizumab 1,200 mg intravenously every 3 weeks, or FAP-IL2v weekly for 4 weeks and then every 2 weeks plus atezolizumab 840 mg intravenously every 2 weeks. The primary endpoint was investigator-assessed objective response rate (ORR).Results:In the ...
This phase I, open-label, multicenter, dose-escalation, and extension study (NCT02627274) evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of FAP-IL2v in patients with advanced/metastatic solid tumors.Neeltje Steeghs...
FAP-IL2v实现黑色素瘤患者持续缓解长达43.4个月! Simlukafusp alfa (FAP-IL2v)是一种单体免疫细胞因子,2024年7月1日,《CLINICAL CANCER RESEARCH》发表了FAP-IL2v在晚期/转移性实体瘤患者中的I期临床(NCT02627274)疗效,在该试验中,FAP-IL2v显示出初步抗肿瘤活性。